EHC Quote, Financials, Valuation and Earnings

HCA Healthcare has a net margin of 10.41% compared to Encompass Health's net margin of 8.79%. Encompass Health's return on equity of 18.4% beat HCA Healthcare's return on equity of 822.75%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 22.65%. On the other hand HCA Healthcare has an analysts' consensus of $389.15 which suggests that it could grow by 4.67%. Given that Encompass Health has higher upside potential than HCA Healthcare, analysts believe Encompass Health is more attractive than HCA Healthcare.

Encompass Health has a beta of 0.901, which suggesting that the stock is 9.914% less volatile than S&P 500. In comparison HCA Healthcare has a beta of 1.473, suggesting its more volatile than the S&P 500 by 47.282%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.63%. HCA Healthcare offers a yield of 0.74% to investors and pays a quarterly dividend of $0.72 per share. Encompass Health pays 13.78% of its earnings as a dividend. HCA Healthcare pays out 11.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are smaller than HCA Healthcare quarterly revenues of $18.3B. Encompass Health's net income of $151.5M is lower than HCA Healthcare's net income of $1.6B. Notably, Encompass Health's price-to-earnings ratio is 22.17x while HCA Healthcare's PE ratio is 16.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.99x versus 1.34x for HCA Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of 10.41% compared to Encompass Health's net margin of 4.52%. Encompass Health's return on equity of 18.4% beat Pediatrix Medical Group's return on equity of -10.7%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 22.65%. On the other hand Pediatrix Medical Group has an analysts' consensus of $17.14 which suggests that it could grow by 33.82%. Given that Pediatrix Medical Group has higher upside potential than Encompass Health, analysts believe Pediatrix Medical Group is more attractive than Encompass Health.

Encompass Health has a beta of 0.901, which suggesting that the stock is 9.914% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.254, suggesting its more volatile than the S&P 500 by 25.37%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.63%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than Pediatrix Medical Group quarterly revenues of $458.4M. Encompass Health's net income of $151.5M is higher than Pediatrix Medical Group's net income of $20.7M. Notably, Encompass Health's price-to-earnings ratio is 22.17x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.99x versus 0.55x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 10.41% compared to Encompass Health's net margin of -18.76%. Encompass Health's return on equity of 18.4% beat The Oncology Institute's return on equity of -340.01%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 22.65%. On the other hand The Oncology Institute has an analysts' consensus of $6.50 which suggests that it could grow by 135.69%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

Encompass Health has a beta of 0.901, which suggesting that the stock is 9.914% less volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.017, suggesting its less volatile than the S&P 500 by 98.311%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.63%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than The Oncology Institute quarterly revenues of $104.4M. Encompass Health's net income of $151.5M is higher than The Oncology Institute's net income of -$19.6M. Notably, Encompass Health's price-to-earnings ratio is 22.17x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.99x versus 0.56x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 10.41% compared to Encompass Health's net margin of 6.97%. Encompass Health's return on equity of 18.4% beat US Physical Therapy's return on equity of 4.62%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 22.65%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 44.89%. Given that US Physical Therapy has higher upside potential than Encompass Health, analysts believe US Physical Therapy is more attractive than Encompass Health.

Encompass Health has a beta of 0.901, which suggesting that the stock is 9.914% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.202%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.63%. US Physical Therapy offers a yield of 2.43% to investors and pays a quarterly dividend of $0.45 per share. Encompass Health pays 13.78% of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but US Physical Therapy's is not.

Encompass Health quarterly revenues are $1.5B, which are larger than US Physical Therapy quarterly revenues of $183.8M. Encompass Health's net income of $151.5M is higher than US Physical Therapy's net income of $12.8M. Notably, Encompass Health's price-to-earnings ratio is 22.17x while US Physical Therapy's PE ratio is 33.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.99x versus 1.58x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.